

**Characterisation of Substance P and Transient  
Receptor Potential Melastatin Channel Messenger  
RNA and Protein Expression in Acute and Chronic  
Neurological Disorders**

Naomi L. Cook  
BMedSc (Hons)

Discipline of Pathology,  
School of Medical Sciences,  
The University of Adelaide

December, 2009

A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of  
Philosophy

# Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Naomi Cook

Date

# Acknowledgements

I would like to express my appreciation to the following people who have helped me during my candidature.

To my supervisors, Prof. Robert Vink and Dr. Corinna Van Den Heuvel, for the opportunity to undertake my PhD in your laboratory, your advice and for everything you have taught me.

To Jim Manavis, for optimising the TRPM channel antibodies and helping to organise my human FFPE tissue cases.

To the Victorian Brain Bank Network, in particular David O'Reilly and Fairlie Hinton, for help in acquiring post-mortem, fresh frozen, human brain tissue for both the TBI and PD studies.

To Robyn Flook of the South Australian Brain Bank for providing post-mortem, fresh frozen, human PD tissue.

To Dr. Emma Thornton and Mark Hassall for carrying out the animal work for the PD study.

To Dr. Stephen Helps, for analysing my immunohistochemistry data.

To Frances Corrigan, for helping me complete my animal work so quickly.

To Bernice Gutschmidt, Emma Thornton and Justin Mencil, for helping to cut my FFPE blocks.

To our research team for your friendship and support.

To the Medical School staff for administrative support and Centre For Neurological Diseases staff for help in the laboratory over the years.

To the Neurosurgical Research Foundation for providing equipment used in this project

To the NH&MRC for financial support in awarding me a biomedical postgraduate scholarship.

# Publications Arising From This Thesis

The following articles were published or accepted for publication during my PhD candidature, and sections of these articles appear in the present thesis.

## Published Articles

**Cook N. L.**, Vink, R., Donkin, J. J. and Van Den Heuvel, C. (2009) Validation of reference genes for normalisation of real-time quantitative RT-PCR data in traumatic brain injury. *Journal of Neuroscience Research* 87:34–41.

Vink, R., **Cook, N. L.** and Van Den Heuvel, C. (2009) Magnesium in acute and chronic brain injury: an update. *Magnesium Research* 22(3):1–5.

**Cook, N. L.**, Van Den Heuvel, C. and Vink, R. (2009) Are the transient receptor potential melastatin (TRPM) channels important in magnesium homeostasis following traumatic brain injury? *Magnesium Research* 22(4):225–234.

**Cook, N. L.**, Kleinig, T. J., Van Den Heuvel, C. and Vink R. (2010) Reference genes for normalising gene expression data in collagenase-induced rat intracerebral haemorrhage. *BMC Molecular Biology* 11:7.

**Cook, N. L.**, Vink, R., Helps, S. C., Manavis, J. and Van Den Heuvel, C. (2010) Transient receptor potential melastatin 2 expression is increased following experimental traumatic brain injury in rats. *Journal of Molecular Neuroscience* doi: 10.1007/s12031-010-9347-8.

## **Published Abstracts**

**Cook, N. L.**, Van Den Heuvel, C. and Vink, R. (2009) Characterisation of TRPM channel messenger RNA levels in traumatic brain injury. *Journal of Neurotrauma* 26:A73.

**Cook, N. L.**, Van Den Heuvel, C. and Vink, R. (2009) Characterisation of TRPM channel mRNA levels in Parkinson's Disease. *Magnesium Research* 22:188S-189S.

Kleinig, T. J., Helps, S. C., **Cook, N. L.**, Blumbergs, P. C., Vink, R. (2010) Inhibition of substance P reduces oedema and blood-brain barrier dysfunction following rat collagenase intracerebral haemorrhage, but does not improve functional outcome. *Stroke* 41(4):e13.

# Conference Presentations

**Neurotrauma 2009, Santa Barbara, USA** The Second Joint Symposium of the International and National Neurotrauma Societies.

Poster Presenter: Characterisation of TRPM channel messenger RNA levels in traumatic brain injury by **Cook, N. L.**, Van Den Heuvel, C. and Vink, R.

**Magnesium 2009, Iasi, Romania** 12th International Magnesium Symposium.

Invited Speaker: Characterisation of TRPM channel mRNA levels in Parkinson's Disease by **Cook, N. L.**, Van Den Heuvel, C. and Vink, R.

**The University of Adelaide** Faculty of Health Sciences Poster Expo, 2009.

Poster Presenter: Quantification of TRPM channel messenger RNA levels in the rat hippocampus following traumatic brain injury by **Cook, N. L.**, Van Den Heuvel, C. and Vink, R.

**The University of Adelaide** Faculty of Health Sciences Poster Expo, 2008.

Poster Presenter: Validation of reference genes for normalisation of real-time quantitative RT-PCR data in traumatic brain injury by **Cook, N. L.**, Donkin, J. J., Vink, R. and Van Den Heuvel, C.

# Table of Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
1.1	Acute Neurological Disorders	1
1.2	Traumatic Brain Injury	1
1.2.1	Epidemiology	1
1.2.2	Pathology	1
	Diffuse Axonal Injury	2
	Oedema	2
	Oxidative Stress	3
	Mitochondrial Dysfunction	4
	Inflammation	5
	Magnesium Decline	5
1.2.3	Physiological Role of Magnesium	6
	Functions	6
	Neuroprotection in TBI	7
	Deficiency	7
	Homeostasis and Transport	8
1.2.4	TRPM Channels and Acute Brain Injury	9
1.3	Chronic Neurological Disorders	10
1.4	Parkinson's Disease	10
1.4.1	Epidemiology	10
1.4.2	Pathology	10
1.4.3	Aetiology	11
	Genetic Factors	11
	Environmental Factors	12
	Inflammation	13
	Oxidative Stress	15
	Mitochondrial Dysfunction	17
1.4.4	Treatments	18
1.4.5	Substance P and PD	19
1.4.6	TRPM Channels and Magnesium in PD	20
1.5	The Transient Receptor Potential Channel Family	22

1.5.1	Overview	22
1.5.2	The Transient Receptor Potential Melastatin Family	22
1.5.3	TRPM7	23
	Permeability	23
	Protein Kinase Activity	24
	Regulation of TRPM7 Activity	25
	Role in Cell Viability	26
	Role in Synaptic Transmission	26
	Role in CNS Pathology	27
1.5.4	TRPM6	29
	Properties	29
	Multimerisation with TRPM7	30
	Hypomagnesaemia with Secondary Hypocalcaemia	30
1.5.5	TRPM3	31
1.5.6	TRPM2	32
	Properties and Localisation	32
	Activation	32
	Role in Cell Death	33
	Genetic Variants of TRPM2	33
1.6	Substance P	34
1.6.1	History	34
1.6.2	The Mammalian Tachykinins	34
	Overview	34
	Synthesis	35
	Distribution	35
	Release and Metabolism	35
	Neurokinin Receptors	36
1.6.3	Biological Effects of SP	37
	Neurotransmission and Nociception	37
	Inflammation	37
	SP in CNS Disorders	37
<b>2</b>	<b>Real-time RT-PCR</b>	<b>39</b>
2.1	Introduction to PCR	39
2.2	Reverse Transcription PCR	40
2.3	Quantitative, Real-time RT-PCR	41
2.3.1	The Real-time RT-PCR Assay	41
	Detection Chemistries	42
	Data Analysis	43
2.3.2	Normalisation	44



<b>3</b>	<b>Materials and Methods</b>	<b>48</b>
3.1	Materials . . . . .	48
3.2	Methods . . . . .	50
3.2.1	Animal Ethics and Care . . . . .	50
3.2.2	Rodent Model of Traumatic Brain Injury . . . . .	50
	Animal Sacrifice . . . . .	51
3.2.3	Rodent Models of Parkinson’s Disease . . . . .	52
	Animal Sacrifice . . . . .	53
3.2.4	Immunohistochemistry . . . . .	53
	Haematoxylin and Eosin Staining . . . . .	53
	SP and TRPM Channel Immunohistochemistry . . . . .	54
3.2.5	RNA Extraction . . . . .	55
3.2.6	Reverse Transcription . . . . .	56
3.2.7	Real-time RT-PCR . . . . .	57
	Primer Design . . . . .	57
	Real-time PCR Amplification . . . . .	58
	Reference Gene Stability and Data Analysis . . . . .	59
	Statistical Analysis . . . . .	59
<b>4</b>	<b>Reference Gene Validation</b>	<b>62</b>
4.1	Introduction . . . . .	62
4.2	Materials and Methods . . . . .	64
4.2.1	RNA Extraction and Reverse Transcription . . . . .	64
4.2.2	Real-time RT-PCR . . . . .	64
4.2.3	PCR Data Analysis . . . . .	64
4.3	Results . . . . .	65
4.3.1	RNA Quality . . . . .	65
4.3.2	Reference Gene Stability . . . . .	65
4.3.3	SP Normalised to Individual Reference Genes . . . . .	66
4.4	Discussion . . . . .	67
<b>5</b>	<b>SP Expression In TBI</b>	<b>69</b>
5.1	Introduction . . . . .	69
5.2	Materials and Methods . . . . .	70
5.2.1	Rodent Model of TBI . . . . .	70
5.2.2	Human TBI Cases . . . . .	70
5.2.3	RNA Extraction and Real-time RT-PCR . . . . .	71
5.2.4	SP Immunohistochemistry . . . . .	71
5.2.5	Statistical Analysis . . . . .	71
5.3	Results . . . . .	72

5.3.1	RNA Quality . . . . .	72
5.3.2	SP mRNA Quantification . . . . .	72
5.3.3	SP Immunohistochemistry . . . . .	73
5.4	Discussion . . . . .	74
<b>6</b>	<b>TRPM Channel Expression In TBI</b>	<b>78</b>
6.1	Introduction . . . . .	78
6.2	Materials and Methods . . . . .	81
6.2.1	Rodent Model of TBI . . . . .	81
6.2.2	Human TBI Cases . . . . .	81
6.2.3	RNA Extraction and Real-time RT-PCR . . . . .	82
6.2.4	TRPM Channel Immunohistochemistry . . . . .	82
6.2.5	Statistical Analysis . . . . .	82
6.3	Results . . . . .	83
6.3.1	TRPM2 Expression . . . . .	83
6.3.2	TRPM3 Expression . . . . .	84
6.3.3	TRPM7 Expression . . . . .	86
6.3.4	TRPM6 Expression . . . . .	87
6.4	Discussion . . . . .	88
6.4.1	TRPM2 . . . . .	88
6.4.2	TRPM3 . . . . .	90
6.4.3	TRPM7 . . . . .	91
6.4.4	TRPM6 . . . . .	94
6.4.5	Conclusions . . . . .	95
<b>7</b>	<b>SP Gene Expression in PD</b>	<b>96</b>
7.1	Introduction . . . . .	96
7.2	Materials and Methods . . . . .	98
7.2.1	Rodent Models of PD . . . . .	98
7.2.2	Human PD Cases . . . . .	99
7.2.3	RNA Extraction and Real-time RT-PCR . . . . .	99
7.2.4	Statistical Analysis . . . . .	99
7.3	Results . . . . .	100
7.3.1	Experimental PD . . . . .	100
7.3.2	Clinical PD . . . . .	100
7.4	Discussion . . . . .	100
<b>8</b>	<b>TRPM Channel Expression in PD</b>	<b>104</b>
8.1	Introduction . . . . .	104
8.2	Materials and Methods . . . . .	107
8.2.1	Rodent Models of PD . . . . .	107

8.2.2	Human PD Cases . . . . .	108
8.2.3	RNA Extraction and Real-time RT-PCR . . . . .	108
8.2.4	TRPM Channel Immunohistochemistry . . . . .	108
8.2.5	Statistical Analysis . . . . .	109
8.3	Results . . . . .	109
8.3.1	Rodent Models of PD . . . . .	109
8.3.2	Clinical PD . . . . .	111
8.4	Discussion . . . . .	112
8.4.1	TRPM2 . . . . .	112
8.4.2	TRPM3 . . . . .	115
8.4.3	TRPM7 . . . . .	116
8.4.4	Conclusions . . . . .	119
<b>9</b>	<b>General Discussion</b>	<b>120</b>
<b>A</b>	<b>Appendix - Gene Expression Analysis in FFPE Tissue</b>	<b>130</b>
A.1	Pilot Studies . . . . .	130
A.1.1	Background . . . . .	130
A.1.2	Experimental Procedures . . . . .	130
RNA Extraction	. . . . .	131
A.1.3	Real-time RT-PCR . . . . .	132
Conclusions	. . . . .	133
<b>B</b>	<b>Appendix - Clinical Information</b>	<b>134</b>
B.1	Details of Post Mortem Human Brain Tissue . . . . .	134
B.1.1	TBI Tissue . . . . .	134
B.1.2	PD Tissue . . . . .	134
<b>C</b>	<b>Appendix - Rat TBI Micrographs</b>	<b>137</b>
<b>D</b>	<b>Appendix - Human TBI Micrographs</b>	<b>149</b>
	<b>Bibliography</b>	<b>153</b>

# List of Figures

1.1	Consequences of Blood-Brain Barrier Disruption . . . . .	15
1.2	Dopamine Synthesis and Metabolism . . . . .	16
1.3	General Structure of TRP Channels . . . . .	22
1.4	Structural Diagram of TRPM Channels . . . . .	23
1.5	Mechanisms of TRPM7 Regulation by GPCR . . . . .	26
1.6	TRPM7 Channel Activation During Ischaemia . . . . .	29
1.7	Alternative Splicing of Human TAC1, TAC3 and TAC4 Genes . . . . .	36
2.1	Diagram of the PCR Process . . . . .	40
2.2	Example of an Agarose Gel . . . . .	40
2.3	Real-time PCR Amplification and Standard Curves . . . . .	42
2.4	Melt Curve Analysis . . . . .	43
3.1	Induction of Rodent TBI . . . . .	51
4.1	geNorm Ranking of Reference Genes in Rat TBI . . . . .	66
4.2	SP mRNA Level Normalised to Individual Reference Genes . . . . .	67
5.1	Bioanalyzer Assessment of RNA Integrity . . . . .	72
5.2	SP mRNA Level Following TBI . . . . .	73
5.3	SP Immunoreactivity Following TBI . . . . .	74
5.4	SP Protein Expression Following TBI . . . . .	74
6.1	TRPM2 Expression Following TBI . . . . .	83
6.2	TRPM3 Expression Following TBI . . . . .	85
6.3	TRPM7 Expression Following TBI . . . . .	86
6.4	TRPM6 Expression Following TBI . . . . .	88
6.5	Potential Mechanisms of TRPM Channel-Mediated Cell Death in TBI . . . . .	93
7.1	Brain Regions Investigated in Human PD Study . . . . .	99
7.2	SP mRNA Level in PD . . . . .	100
8.1	TRPM2 Expression in Experimental PD . . . . .	110
8.2	TRPM3 Expression in Experimental PD . . . . .	110

8.3	TRPM7 Expression in Experimental PD . . . . .	111
8.4	TRPM Channel mRNA Levels in Clinical PD . . . . .	111
8.5	TRPM Channel Staining of Rat Striatum . . . . .	112
8.6	TRPM Channel Staining of Rat SN . . . . .	113
9.1	Potential Interaction Between SP and TRPM7 in CNS Disorders . . . . .	129
A.1	Electropherograms from the Agilent Bioanalyzer . . . . .	132
A.2	Real-time PCR Amplification Curves - FFPE tissue RNA (1) . . . . .	132
A.3	Real-time PCR Amplification Curves - FFPE tissue RNA (2) . . . . .	133
C.1	H & E Staining of Rat TBI Cerebral Cortex . . . . .	138
C.2	H & E Staining of Rat TBI Hippocampus - CA1 Region . . . . .	139
C.3	H & E Staining of Rat TBI Hippocampus - Dentate Gyrus . . . . .	140
C.4	TRPM2 Staining of Rat TBI Cerebral Cortex . . . . .	141
C.5	TRPM2 Staining of Rat TBI Hippocampus . . . . .	142
C.6	TRPM3 Staining of Rat TBI Cerebral Cortex . . . . .	143
C.7	TRPM3 Staining of Rat TBI Hippocampus . . . . .	144
C.8	TRPM7 Staining of Rat TBI Cerebral Cortex . . . . .	145
C.9	TRPM7 Staining of Rat TBI Hippocampus . . . . .	146
C.10	TRPM6 Staining of Rat TBI Cerebral Cortex . . . . .	147
C.11	TRPM6 Staining of Rat TBI Hippocampus . . . . .	148
D.1	H & E Staining of Clinical TBI Cases - Parietal Cortex . . . . .	150
D.2	H & E Staining of Clinical TBI Cases - Hippocampus . . . . .	150
D.3	TRPM2 Staining of Clinical TBI Cases . . . . .	151
D.4	TRPM3 Staining of Clinical TBI Cases . . . . .	151
D.5	TRPM7 Staining of Clinical TBI Cases . . . . .	152

# List of Tables

3.1	Immunohistochemistry Antibodies . . . . .	54
3.2	Human Primer Sequences . . . . .	60
3.3	Rat Primer Sequences . . . . .	61
4.1	Reference Gene Validation - TBI . . . . .	66
4.2	Reference Gene Validation - Rat PD . . . . .	66
4.3	Reference Gene Validation - Human PD . . . . .	67
8.1	Summary of PD Study Design - TRPM Channel Expression . . . . .	107
A.1	RNA Concentrations – FFPE Tissue . . . . .	131
A.2	RNA Integrity – FFPE Tissue . . . . .	131
B.1	Human TBI Tissue – Fresh Frozen . . . . .	135
B.2	Human TBI Tissue – FFPE . . . . .	136
B.3	Human PD & Control Tissue . . . . .	136

# List of Abbreviations

6-OHDA	6-hydroxydopamine
ACE	Angiotensin Converting Enzyme
ACTB	<i>β</i> -actin
AD	Alzheimer's Disease
ADP	Adenosine Diphosphate
ADPR	Adenosine Diphosphoribose
AET	Anti-Excitotoxic Therapy
AIHW	Australian Institute of Health and Welfare
ALS	Amyotrophic Lateral Sclerosis
ALS-G	Amyotrophic Lateral Sclerosis of Guam
AMP	Adenosine Monophosphate
APP	Amyloid Precursor Protein
ATP	Adenosine Triphosphate
B2MG	<i>β</i> -2-microglobulin
Ba <sup>2+</sup>	Barium
BBB	Blood-Brain Barrier
BG	Basal Ganglia
bp	Base Pairs
Ca <sup>2+</sup>	Calcium
cAMP	Cyclic AMP

Cd <sup>2+</sup>	Cadmium
cDNA	Complementary DNA
CNS	Central Nervous System
Co <sup>2+</sup>	Cobalt
CSF	Cerebrospinal Fluid
Ct	Cycle Threshold
Cu <sup>2+</sup>	Copper
DA	Dopamine
DAB	3, 3'-diaminobenzidine tetrahydrochloride
DAG	Diacylglycerol
DAI	Diffuse Axonal Injury
DNA	Deoxyribonucleic Acid
DNase	Deoxyribonuclease
dNTP	Deoxynucleoside Triphosphate
ds	Double-stranded
dsDNA	Double-stranded DNA
EDTA	Ethylenediaminetetraacetic Acid
FAD	Familial Alzheimer's Disease
Fe <sup>2+</sup>	Ferrous Iron
Fe <sup>3+</sup>	Ferric Iron
FFPE	Formalin-Fixed, Paraffin-Embedded
GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase
Gd <sup>3+</sup>	Gadolinium
gDNA	Genomic DNA
GP	Globus Pallidus
GPCR	G-Protein-Coupled Receptor



GTP	Guanosine Triphosphate
GUSB	$\beta$ -glucuronidase
H & E	Haematoxylin and Eosin
H <sub>2</sub> O <sub>2</sub>	Hydrogen Peroxide
HMBS	Hydroxymethylbilane Synthase
HPRT	Hypoxanthine Guanine Phosphoribosyltransferase
HSH	Hypomagnesaemia with Secondary Hypocalcaemia
ICP	Intracranial Pressure
IgG	Immunoglobulin G
IL	Interleukin
IMVS	Institute of Medical and Veterinary Science
IP <sub>3</sub>	Inositol 1,4,5-triphosphate
IU	International Units
K <sup>+</sup>	Potassium
L	litre
L-DOPA	L-3,4-dihydroxyphenylalanine (levodopa)
LRRK	Leucine-Rich Repeat Kinase
M	Molar
MAO	Monoamine Oxidase
MFB	Medial Forebrain Bundle
Mg <sup>2+</sup>	Magnesium
MgSO <sub>4</sub>	Magnesium Sulphate
Mn <sup>2+</sup>	Manganese
MPP <sup>+</sup>	1-methyl-4-phenylpyridinium
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mRNA	Messenger RNA

MTG	Mid-Temporal Gyrus
Na <sup>+</sup>	Sodium
NAD	Nicotinamide Adenine Dinucleotide
NAT	N-acetyl-tryptophan
NH&MRC	National Health and Medical Research Council
NHS	Normal Horse Serum
Ni <sup>2+</sup>	Nickel
NK-1R	Neurokinin-1 Receptor
NKA	Neurokinin A
NKB	Neurokinin B
NMDA	N-methyl-D-aspartate
NMDAR	N-methyl-D-aspartate Receptor
NO	Nitric Oxide
NUDT9	Nudix (nucleoside diphosphate linked moiety X)-type motif 9
O <sub>2</sub> <sup>-</sup>	Superoxide
OGD	Oxygen-Glucose Deprivation
OH•	Hydroxyl Radical
ONOO <sup>-</sup>	Peroxynitrite
PARP	poly(ADP-ribose) polymerase
PBS	Phosphate Buffered Saline
PCR	Polymerase Chain Reaction
PD	Parkinson's Disease
PD-G	Parkinsonism Dementia Complex of Guam
PIP <sub>2</sub>	Phosphatidylinositol 4,5-bisphosphate
PKA	Protein Kinase A
PLC	Phospholipase C

PNS	Peripheral Nervous System
POL2R	RNA Polymerase II
PPT	Preprotachykinin
PS	Pregnenolone Sulphate
PTEN	Phosphatase and Tensin homolog
R <sup>2</sup>	Coefficient of Determination
RIN	RNA Integrity Number
RNA	Ribonucleic Acid
RNase	Ribonuclease
RNS	Reactive Nitrogen Species
ROS	Reactive Oxygen Species
RPL13A	Ribosomal Protein L13A
rpm	Revolutions Per Minute
rRNA	Ribosomal RNA
RT	Reverse Transcription
RT-PCR	Reverse Transcription Polymerase Chain Reaction
SD	Standard Deviation
SDHA	Succinyl Dehydrogenase Subunit A
SEM	Standard Error of the Mean
SN	Substantia Nigra
SNpc	Substantia Nigra pars compacta
SP	Substance P
SPC	Streptavidin-Peroxidase Complex
Sr <sup>2+</sup>	Strontium
TAC1	Tachykinin, Precursor 1
TBI	Traumatic Brain Injury

TBP	TATA Box Binding Protein
TGF- $\beta$	Transforming Growth Factor- $\beta$
TM	Transmembrane
TNF- $\alpha$	Tumour Necrosis Factor- $\alpha$
TRP	Transient Receptor Potential
TRPM	Transient Receptor Potential Melastatin
V	Volts
Zn <sup>2+</sup>	Zinc
°C	Degrees Celsius

# Abstract

Traumatic brain injury (TBI) is the leading cause of death and disability in people under 40 years of age, with motor vehicle incidents accounting for the majority of severe TBI cases. Despite the public health burden of TBI, there are no effective treatment options available, with survivors often left with debilitating long-term deficits. Following TBI, a cascade of pathophysiological processes is initiated in the central nervous system, including oedema, inflammation, magnesium decline and oxidative stress. These factors play a role in the high morbidity and mortality following TBI, however, their underlying molecular mechanisms remain poorly understood.

Parkinson's Disease (PD) is a common neurodegenerative disease and affects approximately 1 % of the population over 65 years of age. PD is characterised by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to a reduction of dopamine levels in the striatum. The pathogenesis of PD is poorly understood, but is likely to involve oxidative stress and inflammatory processes. Current treatments that replace dopamine lose efficacy after several years.

Treatments for TBI and PD are thus urgently required; this requires a greater understanding of the pathophysiology of these disorders at a molecular level. Recent studies from our laboratory have demonstrated a link between the neuropeptide, substance P (SP), and the development of cerebral oedema and neurologic deficits following TBI, which are attenuated with the administration of an NK-1 (neurokinin-1, SP receptor) antagonist. In addition, studies using a rat model of PD have similarly established a putative role for SP in this disease process.

Transient receptor potential melastatin (TRPM) channels are a diverse family of ion channels, many of which are highly expressed in the brain. It is likely that TRPM7 and TRPM6 regulate cellular magnesium homeostasis. TRPM7 and TRPM2 are critical mediators of ischaemic neuronal death, and mutations in the TRPM7 and TRPM2 genes confer a genetic susceptibility to parkinsonism. The function of TRPM3 is not well understood, but evidence suggests it may be involved in brain function.

The aims of the present thesis were to: quantify the mRNA level and protein expression of SP, TRPM2, TRPM3, TRPM6 and TRPM7 channels following TBI in human clinical cases and over a time course of experimental TBI in rats; and to characterise the mRNA level of

SP, TRPM2, TRPM3 and TRPM7 channels in both clinical PD cases and two rodent models of PD (early and late disease stage), and the protein expression of TRPM channels in early experimental PD.

We demonstrate an upregulation of SP expression in clinical and experimental TBI, supporting our previous studies implicating SP release with TBI pathophysiology. Changes in TRPM channel expression at both the transcript and protein level were also observed following both TBI and in PD, suggesting that TRPM channels may contribute to the oxidative stress, inflammation and neuronal death associated with these disorders. This thesis provides novel information regarding the molecular mechanisms underlying TBI and PD, which is relevant to the development of effective treatment strategies.